The Journal of Liquid Biopsy最新文献

{"title":"Liquid biopsy in gastric cancer: A snapshot of the current state of the art","authors":"Jessica Gasparello ,&nbsp;Carlotta Ceccon ,&nbsp;Valentina Angerilli ,&nbsp;Tatiane Comunello ,&nbsp;Marianna Sabbadin ,&nbsp;Felipe D'Almeida Costa ,&nbsp;Antonio Antico ,&nbsp;Claudio Luchini ,&nbsp;Paola Parente ,&nbsp;Francesca Bergamo ,&nbsp;Sara Lonardi ,&nbsp;Matteo Fassan","doi":"10.1016/j.jlb.2025.100288","DOIUrl":"10.1016/j.jlb.2025.100288","url":null,"abstract":"<div><div>Circulating tumor DNA (ctDNA) is nowadays considered a robust source to search for druggable tumoral genetic alterations, and in some specific settings liquid biopsy (LB) is already part of the diagnostics scenario and it has successfully implemented in the everyday practice. Three strengths make LB an extraordinary tool: i) to represent the complex molecular mosaicism that characterizes spatially heterogeneous malignancies; ii) to monitor in real-time the tumoral molecular landscape (i.e. to depict the longitudinal/temporal tumor evolution); iii) to ensure molecular profiling even in those cases in which tissue sampling is not feasible or not adequate. This review provides a snapshot of the current state of the art concerning ctDNA assay utility in gastric cancer (GC), testing its robustness as marker and seeking to understand the reasons for the delay in its application in clinical practice.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"7 ","pages":"Article 100288"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential applications of gene expression profiles obtained from circulating extracellular vesicles in breast cancer","authors":"Aritra Gupta ,&nbsp;Siddharth Bhardwaj ,&nbsp;Sayan Ghorai ,&nbsp;Rosina Ahmed ,&nbsp;Sanjit Agarwal ,&nbsp;Geetashree Mukherjee ,&nbsp;Kartiki V. Desai","doi":"10.1016/j.jlb.2025.100287","DOIUrl":"10.1016/j.jlb.2025.100287","url":null,"abstract":"<div><h3>Background</h3><div>Liquid biopsy-based biomarkers offer several advantages since they are minimally invasive, can be useful in longitudinal monitoring of the disease and have higher patient compliance. We describe a protocol using minimal volumes of archival and prospective serum/plasma samples to define the RNA contents of EVs and discuss its benefits and limitations.</div></div><div><h3>Methods</h3><div>RNA-seq analysis of matched tumor biopsy, circulating EVs from breast cancer patients (EV-C, n = 26) and healthy donors (EV-H, n = 4) was performed and differentially expressed genes were validated by RT-PCR in a separate series of samples (EV-C, n = 32 and EV-H, n = 22). A total of 84 samples were studied.</div></div><div><h3>Results</h3><div>RNA-seq data from 500 μl serum samples yielded more than 17000 genes, of which 320 were DEGs (adjusted p value ≤ 0.05) between EV-C and EV-H samples. Pathways for Myc V1, reactive oxygen species, angiogenesis, allograft rejection and Interferon regulated genes were over-represented in EV-C samples. Computational deconvolution algorithms for cell signatures identified immune cells such as Th1 and memory T-cells, endothelial cells, and osteoblasts from the stromal compartment as significant. Top 6 genes were validated by qRT-PCR in all samples (n = 84) and they consistently and correctly classified cancer and healthy groups. An independent set of 374 and 640 DEGs could segregate ER positive/ER negative and non-metastatic versus metastatic samples, respectively. EVs from metastatic samples had higher variability in gene expression patterns whereas those from non-metastatic samples showed a better correlation.</div></div><div><h3>Conclusion</h3><div>By using low serum amounts successfully for EV transcriptomics, we demonstrate that a minimally invasive technique could be converted to a microinvasive format. These data lay the foundation for EV RNA based biomarker discovery for segregating breast cancers.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"7 ","pages":"Article 100287"},"PeriodicalIF":0.0,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PADI4 expression in baseline circulating tumour cells acts as a prognostic biomarker in oral squamous cell carcinoma","authors":"Anshika Chauhan ,&nbsp;Geeta S. Boora ,&nbsp;Arindam Maitra ,&nbsp;Rijuneeta Gupta ,&nbsp;Jaimanti Bakshi ,&nbsp;Sushmita Ghoshal ,&nbsp;Arnab Pal","doi":"10.1016/j.jlb.2025.100289","DOIUrl":"10.1016/j.jlb.2025.100289","url":null,"abstract":"<div><div>Oral Squamous Cell Carcinoma (OSCC), one of the most prevalent cancers in developing countries. It is associated with poor prognosis due to relapse in a significant number of patients. Circulating tumour cells (CTCs) are precursors for metastasis and thought to be key players in early relapse in various cancers including OSCC. Though CTC enumeration has been associated with disease outcome, in-depth molecular analysis of CTCs remained minimal as the techniques for CTC isolation and analysis are challenging. While exploring gene expression in CTCs, we performed whole transcriptome analysis of paired primary tumour and CTCs isolated from Oral Squamous Cell Carcinoma (OSCC) patients. Various genes were found to be differentially expressed in CTCs. We found PADI4 gene was significantly upregulated in CTCs. PADI4 gene encodes for an enzyme that converts arginine to citrulline.</div><div>PADI4 expression in primary tumours was previously observed to be associated with metastasis. Here, we are reporting PADI4 expression for the first time in CTCs and its association with relapse. Interestingly in our data, PADI4 expression was more seen in CTCs with EMT (epithelial to mesenchymal transition)-phenotype than with CTCs only epithelial-phenotype. In conclusion, this is the first study presenting the potential prognostic utility of PADI4 expression in CTCs isolated from OSCC patients.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"7 ","pages":"Article 100289"},"PeriodicalIF":0.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer in a drop: Liquid biopsy highlights from San Antonio Breast Cancer Symposium (SABCS) 2024","authors":"Letizia Pontolillo ,&nbsp;Mohamed A. Gouda ,&nbsp;Konstantinos Venetis ,&nbsp;Eleonora Nicolò ,&nbsp;Carolina Reduzzi","doi":"10.1016/j.jlb.2025.100286","DOIUrl":"10.1016/j.jlb.2025.100286","url":null,"abstract":"","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"7 ","pages":"Article 100286"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of molecular biomarkers in the diagnosis, prognosis, and treatment stratification of oral squamous cell carcinoma: A comprehensive review","authors":"Saravanan Ravindran ,&nbsp;Srinivasan Ranganathan ,&nbsp;Karthikeyan R ,&nbsp;Nandini J ,&nbsp;Shanmugarathinam A ,&nbsp;Senthil Kumar Kannan ,&nbsp;Durga Prasad K ,&nbsp;Jalaiah Marri ,&nbsp;Rajaganapathi K","doi":"10.1016/j.jlb.2025.100285","DOIUrl":"10.1016/j.jlb.2025.100285","url":null,"abstract":"&lt;div&gt;&lt;div&gt;One of the most common cancers targeting the area of the head and neck is oral squamous cell carcinoma (OSCC), carrying a heavy global health cost. With a high incidence of metastasis and recurrence, the outlook for OSCC remains dismal despite advancements in treatment. This has sparked an investigation into molecular biomarkers, which have the potential to improve early diagnosis, forecast patient outcomes, and direct therapeutic approaches. An extensive summary of the function of molecular biomarkers in OSCC diagnosis, prognosis, and medical care stratification is given in this article. Complex genetic mutations, epigenetic changes, and dysregulated signalling pathways are all part of the aetiology of OSCC. &lt;em&gt;Tumor protein p53&lt;/em&gt; (Tp53), &lt;em&gt;Epidermal growth factor receptor&lt;/em&gt; (EGFR-targeted), &lt;em&gt;Cyclin D1&lt;/em&gt; (CCND1), and &lt;em&gt;Human papilloma virus&lt;/em&gt; (HPV) status are examples of molecular biomarkers that have demonstrated potential in recognising disease at an early stage and identifying malignant changes. The non-invasive detection capabilities of diagnostic biomarkers such as salivary proteins, circulating tumour DNA (ctDNA), and &lt;em&gt;microRNAs&lt;/em&gt; are being explored more and more because they may provide early intervention and better patient outcomes. Prognostically, tumour aggressiveness, recurrence risk, and overall survival have all been linked to biomarkers such as &lt;em&gt;matrix metalloproteinases&lt;/em&gt; (MMPs), &lt;em&gt;E-cadherin&lt;/em&gt;, and different cytokines. Furthermore, immune checkpoints such as &lt;em&gt;cytotoxic T-lymphocyte-associated protein 4&lt;/em&gt; (CTLA-4) and &lt;em&gt;programmed death-ligand 1&lt;/em&gt; (PD-L1) are becoming recognised as important markers of the tumour microenvironment's function in the course of the disease and its reaction to immunotherapy. The significance of biomarkers in personalised medicine has been further highlighted by the recognition of subgroups with elevated risk that might gain benefit from more aggressive treatment options thanks to the genetic profiling of OSCC. Predictive biomarkers are essential for therapy classification because they allow therapeutic regimens to be tailored. For example, (K&lt;em&gt;irsten rat sarcoma viral oncogene homologous)&lt;/em&gt; KRAS mutations and EGFR expression influence the effectiveness of targeted therapies, and the existence of specific epigenetic markers influences choices about radiation or chemotherapy. It is expected that the incorporation of multi-omics techniques, which integrate transcriptome, proteome, and genomic data, will improve these tactics and increase accuracy in OSCC treatment. Molecular indicators have the potential to significantly improve the medical treatment of ovarian cancer. Better patient outcomes will eventually result from earlier identification, more precise prognostication, and individualised therapy regimens made possible by advancements in biomarker research. For these biomarkers to be widely used, further research must be done on verifying t","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"7 ","pages":"Article 100285"},"PeriodicalIF":0.0,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients","authors":"Atul Bharde ,&nbsp;Snigdha Nadagouda ,&nbsp;Manoj Dongare ,&nbsp;Kanchan Hariramani ,&nbsp;Madhura Basavalingegowda ,&nbsp;Sumit Haldar ,&nbsp;Alain D'Souza ,&nbsp;Bhagwat Jadhav ,&nbsp;Sangeeta Prajapati ,&nbsp;Vikas Jadhav ,&nbsp;Sujit Joshi ,&nbsp;Aravindan Vasudevan ,&nbsp;Mohan Uttarwar ,&nbsp;Wenhui Zhou ,&nbsp;Sirish Kishore ,&nbsp;Kumar Prabhash ,&nbsp;Jayant Khandare ,&nbsp;Gowhar Shafi","doi":"10.1016/j.jlb.2024.100284","DOIUrl":"10.1016/j.jlb.2024.100284","url":null,"abstract":"<div><div>A minimally invasive analysis of plasma cell-free DNA (cfDNA) offers a genomic profiling of early-stage breast cancer (EBC), potentially identifying mutational signatures linked to metastasis and therapy resistance. In this study, paired plasma and tissue samples from 40 hormone receptor-positive (HR+) EBC patients were sequenced using a custom-designed comprehensive gene panel, OncoIndx. The genomic landscape of circulating tumor DNA (ctDNA) showed a broader mutation spectrum compared to tumor tissue DNA (tDNA), and provided reliable assessments of microsatellite instability (MSI), tumor mutation burden (TMB), homologous recombination deficiency (HRD), and loss of heterogeneity (LOH), all indicating high genomic instability. Importantly, early detection of estrogen receptor α (<em>ESR1</em>) mutations in ctDNA was achieved, highlighting its potential to identify patients at risk for endocrine resistance, a standard of care for HR + breast tumors. Mutations, particularly in DNA damage response (DDR) and proliferative signaling pathways (phosphatidyl inositol-4,5-bisphosphate 3-kinase; <em>PIK3CA</em>) suggest an increased risk of therapy resistance, pointing to opportunities for risk stratification and tailored treatment strategies in EBC. ctDNA-based liquid biopsy may provide minimally invasive comprehensive genomic analysis of EBC for identifying actionable targets and risk prediction for better disease management.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"7 ","pages":"Article 100284"},"PeriodicalIF":0.0,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic characterization of metastatic patterns in prostate cancer using circulating tumor DNA data from the SCRUM-Japan MONSTAR SCREEN project","authors":"Masaki Shiota ,&nbsp;Nobuaki Matsubara ,&nbsp;Taigo Kato ,&nbsp;Masatoshi Eto ,&nbsp;Takahiro Osawa ,&nbsp;Takashige Abe ,&nbsp;Nobuo Shinohara ,&nbsp;Koshiro Nishimoto ,&nbsp;Yota Yasumizu ,&nbsp;Nobuyuki Tanaka ,&nbsp;Mototsugu Oya ,&nbsp;Takao Fujisawa ,&nbsp;Satoshi Horasawa ,&nbsp;Yoshiaki Nakamura ,&nbsp;Takayuki Yoshino ,&nbsp;Norio Nonomura","doi":"10.1016/j.jlb.2024.100282","DOIUrl":"10.1016/j.jlb.2024.100282","url":null,"abstract":"<div><h3>Purpose</h3><div>Genomic characterization of the predisposition of tumors to metastasize to specific sites has been performed in a few studies using mainly tissue-derived genomes. This nationwide prospective observational study investigated the association between genomic characteristics using circulating tumor DNA (ctDNA), and the synchronous and metachronous metastasis of tumors to specific target organs in advanced prostate cancer.</div></div><div><h3>Methods</h3><div>Patients with advanced prostate cancer undergoing systemic treatment were included. ctDNA was analyzed using the FoundationOne®Liquid CDx assay at enrollment. Associations between genomic characteristics and metastatic status were examined.</div></div><div><h3>Results</h3><div>Alterations in the genes <em>MYC</em>, <em>APC</em>, and <em>BRCA2</em> and the DNA repair, MYC, and WNT pathways were associated with lung and liver metastasis. <em>PTEN</em> gene alterations and PI3K pathway alteration were associated with synchronous lung metastasis. <em>RB1</em> gene alteration and RAS/RAF/MAPK pathway alteration were associated with synchronous liver metastasis. <em>RB1</em> and <em>BRCA2</em> gene alterations predicted metachronous lung metastasis, while <em>TP53</em> and <em>MYC</em> gene alterations predicted metachronous liver metastasis.</div></div><div><h3>Conclusions</h3><div>This study identifies genomic alterations in ctDNA associated with synchronous and metachronous metastases. These findings may be clinically helpful for treating, managing, and monitoring cancer.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"7 ","pages":"Article 100282"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143100031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell-free DNA as a complementary diagnostic tool for neglected tropical diseases towards achieving the WHO NTDs elimination by 2030","authors":"Priscilla Osei-Poku ,&nbsp;Lucienne Tritten ,&nbsp;Fatima Fordjour ,&nbsp;Alexander Kwarteng","doi":"10.1016/j.jlb.2024.100283","DOIUrl":"10.1016/j.jlb.2024.100283","url":null,"abstract":"<div><div>Neglected Tropical Diseases (NTDs) continue to ravage the poorest regions of the world, with over 600 million people being affected in Sub-Saharan Africa. The global burden of NTDs within these regions is staggering, particularly post-COVID-19 pandemic, where the emerging infection intercepted the existing eradication efforts and protocols such as the Mass Drug Administration (MDA). This further complicated the approaches laid down to achieve the endgame program of eliminating the neglect and transmission of NTDs. To compensate for the detriment of COVID-19's interruption, accurate and timely diagnoses play a vital role in attaining the objectives of the WHO's goal of NTD elimination by 2030. To this effect, alternative approaches in diagnostics are urgently needed, particularly with the inadequacy of current diagnostic strategies for NTDs. Cell-free DNA (cfDNA) has shown great promise in detecting NTDs. Several studies have demonstrated its potential for diagnosing diseases such as malaria, leishmaniasis, and schistosomiasis. However, the adoption of cfDNA in NTD research faces several challenges, including the cost of the procedure, standardization, and technical expertise. Proper capacity building and training can mitigate some of these challenges. However, despite these limitations, the affordability of cfDNA detection is improving due to increased awareness of the approach and researchers' integration considerations into current diagnostic routines. In conclusion, while there are challenges to adopting cfDNA in NTD research, it remains a promising alternative strategy to be considered in the fight against NTDs.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"7 ","pages":"Article 100283"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global landscape of liquid biopsy research: Regional contributions and disparities","authors":"Siddig Ibrahim Abdelwahab ,&nbsp;Abdullah Farasani ,&nbsp;Hassan Ahmad Alfaifi ,&nbsp;Waseem Hassan","doi":"10.1016/j.jlb.2024.100165","DOIUrl":"10.1016/j.jlb.2024.100165","url":null,"abstract":"<div><h3>Objective</h3><div>Liquid biopsy has revolutionized cancer research, diagnosis, and personalized treatment. This study aimed to explore regional contributions and disparities in this rapidly advancing field.</div></div><div><h3>Method</h3><div>The Scopus database was utilized for data retrieval in June 2024. A total of 2761 documents, including 1605 articles and 1156 reviews, were analyzed. These documents received 70,837 citations with h-index of 105.</div></div><div><h3>Results</h3><div>Europe was the most prolific region, contributing 1645 documents with 53,728 citations and an h-index of 94. Asia followed with 607 documents, receiving 17,116 citations and an h-index of 62. The Middle East, South America, and Africa had significantly fewer publications, with 44, 41, and 5 documents respectively. The Middle East's publications earned 840 citations and an h-index of 15, South America's documents garnered 725 citations and an h-index of 16, and Africa's modest contribution accumulated 61 citations and an h-index of 3.</div></div><div><h3>Conclusion</h3><div>Despite the remarkable growth and applications of liquid biopsy, significant regional disparities in research contributions and impacts are evident. Addressing these disparities is crucial for ensuring more equitable advancements and access to liquid biopsy technologies worldwide.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"6 ","pages":"Article 100165"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143138987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a novel combinational index of liquid biopsy biomarker for longitudinal lung cancer patient management","authors":"Min-Yi Liao ,&nbsp;Yun-Jie Hao ,&nbsp;Ching-Shan Luo ,&nbsp;Ching-Mei Chen ,&nbsp;Po-Hao Feng ,&nbsp;Hsin-Yu Yang ,&nbsp;Da-Jeng Yao ,&nbsp;Kang-Yun Lee ,&nbsp;Fan-Gang Tseng","doi":"10.1016/j.jlb.2024.100167","DOIUrl":"10.1016/j.jlb.2024.100167","url":null,"abstract":"<div><h3>Objectives</h3><div>Many cancer biomarkers such as the circulating tumor cells/microemboli (CTCs/CTM) have been reported significant associations with clinical outcomes. However, different biomarkers have different sensitivities and specificities for cancer types and cohort patients, and synergistic effects between certain biomarkers have also been observed, leading to the inaccurate, fluctuating, and even controversial results when multiple biomarkers are analyzed together. In this paper, a novel combinational index, P-score, was developed for monitoring and predicting the disease condition of lung cancer patients during follow-up visits.</div></div><div><h3>Materials and methods</h3><div>There were totally 13 return patients with 54 blood samples involved in this study to examine the number of CTC and CTM. Information from one group of 7 patients including 27 blood samples with published clinical data was employed to develop while those from another group of 4 patients containing 14 blood samples with unpublished clinical data were used to validate the P score in prediction. Enumerations were based on immunofluorescent staining images. Distributions of CTC/CTM and their frequencies in stratified patients were carefully examined and analyzed the ROC curve and AUC value to develop the P score and P score-based prediction model.</div></div><div><h3>Results and conclusion</h3><div>We found that the predictive power of P-score was not only comparable to the traditional cancer marker, in comparison with individual CTC/CTM, more false positives could be corrected by using P-score, thereby to improve the accuracy of analysis. From our preliminary validation tests, the prognosis and disease progression monitored longitudinally by P-score were further confirmed by clinical outcome data from physicians and its sensitivity was even better than those from individual biomarkers. We believe that this novel combinational indicator could be a promising tool to interpret clinical outcomes more accurately from multiple factors, particularly useful for the early prognosis and longitudinal monitoring in cancer patient management.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"6 ","pages":"Article 100167"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143138990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}